Visudyne

RSS

verteporfin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Visudyne. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Visudyne.

This EPAR was last updated on 24/09/2019

Authorisation details

Product details
Name
Visudyne
Agency product number
EMEA/H/C/000305
Active substance
verteporfin
International non-proprietary name (INN) or common name
verteporfin
Therapeutic area (MeSH)
  • Myopia, Degenerative
  • Macular Degeneration
Anatomical therapeutic chemical (ATC) code
S01LA01
Publication details
Marketing-authorisation holder
CHEPLAPHARM Arzneimittel GmbH
Revision
33
Date of issue of marketing authorisation valid throughout the European Union
27/07/2000
Contact address

Ziegelhof 24
17489 Greifswald
Germany

Product information

25/07/2019 Visudyne - EMEA/H/C/000305 - T/0100

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Visudyne is indicated for the treatment of:

  • adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;
  • adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
3 ratings